Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of direct oral anticoagulants versus warfarin in patients with single-positive antiphospholipid antibody syndrome: A trinetx cohort analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZAZuhair Alam

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows direct oral anticoagulants reduce bleeding risks in antiphospholipid syndrome, suggesting a viable alternative to warfarin.

Key Points

  • Direct oral anticoagulants were associated with a lower risk of gastrointestinal bleed compared to warfarin, enhancing their safety profile.
  • In the cohort with lupus anticoagulant, DOAC therapy significantly decreased the risks of ischemic stroke and blood transfusion.
  • Propensity score matching was utilized to compare outcomes between patients taking direct oral anticoagulants and those on warfarin.
  • These findings support considering DOACs as an alternative to warfarin in certain antiphospholipid syndrome populations.

Cite This Study

Zuhair Alam (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e350https://doi.org/10.1182/blood-2025-953
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience2025
  2. 2Evaluating the Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Antiphospholipid Syndrome: Updated Systematic Review and Meta-Analysis2025
  3. 3Long-term efficacy and safety of direct oral anticoagulants in venous thrombotic antiphospholipid syndrome patients not candidate to warfarin: A pilot prospective case series study2025
  4. 4Comparative safety and effectiveness of apixaban versus warfarin in antiphospholipid syndrome with chronic kidney disease: A real-world propensity-matched cohort study2025
  5. 5DOACs in Budd-Chiari syndrome: A real-world comparison from the TriNetX Global Collaborative Network2025